A new pill for treating dementia is delivering promising "topline" results in early-stage clinical trials, according to a recent press release by its makers.

Aperture will advance APRTX-001 as a potential treatment for ALS and frontotemporal dementia, with possible expansion for use ...

We break down the current state of frontotemporal dementia, from bvFTD to PPA, and why 'promising' therapies are still far ...

Morgan showed the video to her doctor, and following tests, Lydia was diagnosed with Sanfilippo syndrome B — often called ...

Vascular dementia is a decline in memory, thinking skills, and self-care that occurs due to strokes in the areas of the brain ...

Researchers from DANDRITE have played a central role in developing a new oral treatment that, for the first time ever, has ...

If we haven’t been touched by Alzheimer’s directly, we know someone who has. In fact, more than 7 million Americans aged 65 and older have developed the disease. Compounding this already sobering stat ...

A new report from the National Academies of Sciences, Engineering, and Medicine identified fundamental changes in how scientists approach dementia treatment and prevention. The comprehensive strategy, ...

A hospital has become the first in the country to hire a dementia research nurse to expand clinical trials, improve early ...

Late-breaking oral presentation by a leading global authority in Dementia with Lewy bodies (DLB) to highlight updated data from Phase 2b study on neflamapimod treatment for DLB ...

A major genetic risk factor for delirium has been identified in a study that analyzed the DNA of more than 1 million people ...